We are live on ! Find out more
P

Pfizer Portfolio holdings

AUM $239M
1-Year Est. Return 232.47%
This Fund
S&P 500
This Quarter Est. Return
-25.45%
1 Year Est. Return
+232.47%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$501M
AUM Growth
-$2.09B
Cap. Flow
-$1.9B
Cap. Flow %
-378.75%
Top 10 Hldgs %
96.83%
Holding
23
New
–
Increased
1
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$318K

Top Sells

Rank Stock Value
1
HLN icon
Haleon
HLN
+$1.88B
2
AKRO
Akero Therapeutics
AKRO
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BNTX icon
1
BioNTech
BNTX
$23.1B
$333M 66.51%
3,658,361
– –
ALLO icon
2
Allogene Therapeutics
ALLO
$618M
$32.2M 6.42%
22,032,040
– –
ORIC icon
3
Oric Pharmaceuticals
ORIC
$1.11B
$30M 5.99%
5,376,344
– –
ARVN icon
4
Arvinas
ARVN
$517M
$24.3M 4.85%
3,457,815
– –
TRML
5
DELISTED
Tourmaline Bio
TRML
$19.4M 3.86%
1,272,214
– –
WVE icon
6
Wave Life Sciences
WVE
$1.12B
$15.2M 3.02%
1,875,000
– –
BHVN icon
7
Biohaven
BHVN
$2.32B
$12.2M 2.43%
505,645
– –
CRDF icon
8
Cardiff Oncology
CRDF
$60.2M
$7.57M 1.51%
2,411,575
– –
PYXS icon
9
Pyxis Oncology
PYXS
$150M
$6.89M 1.38%
7,032,770
– –
CRBU icon
10
Caribou Biosciences
CRBU
$164M
$4.28M 0.86%
4,690,431
– –
ZURA icon
11
Zura Bio
ZURA
$518M
$3.83M 0.77%
2,970,022
– –
CELC icon
12
Celcuity
CELC
$4.31B
$3.53M 0.71%
349,406
– –
EPIX
13
DELISTED
ESSA Pharma
EPIX
$2.65M 0.53%
1,675,000
– –
SPRO icon
14
Spero Therapeutics
SPRO
$91.5M
$1.7M 0.34%
2,362,348
– –
ZNTL icon
15
Zentalis Pharmaceuticals
ZNTL
$364M
$1.52M 0.3%
953,834
– –
ANTX icon
16
AN2 Therapeutics
ANTX
$169M
$973K 0.19%
715,295
– –
NXTC icon
17
NextCure
NXTC
$24.4M
$909K 0.18%
157,647
+36,101
+30% +$318K
QTTB icon
18
Q32 Bio
QTTB
$255M
$458K 0.09%
277,777
– –
BOLT icon
19
Bolt Biotherapeutics
BOLT
$8.49M
$250K 0.05%
31,305
– –
SENS icon
20
Senseonics Holdings Inc
SENS
$267M
$28.5K 0.01%
2,171
– –
DNA icon
21
Ginkgo Bioworks
DNA
$517M
$16.7K ﹤0.01%
2,928
– –
AKRO
22
DELISTED
Akero Therapeutics
AKRO
– –
-562,626
Closed -$15.7M
HLN icon
23
Haleon
HLN
$44.5B
– –
-197,228,952
Closed -$1.88B

Similar funds

DCC
Dow Chemical Company Midland, Michigan $239M AUM 13.16% 1-Year Est. Return
OCERS
Orange County Employees Retirement System Santa Ana, California $239M AUM
CWMGP
Capstone Wealth Management Group (Pennsylvania) Clarks Green, Pennsylvania $239M AUM 18.48% 1-Year Est. Return
WWA
Wealth Watch Advisors Englewood, Colorado $239M AUM 21.17% 1-Year Est. Return
MFC
Mechanics Financial Corp Mansfield, Ohio $239M AUM 25.61% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return
TGIA
Torrey Growth & Income Advisors Del Mar, California $239M AUM
GCA
Genesee Capital Advisors Auburn, New York $239M AUM 20.45% 1-Year Est. Return

Pfizer's Q1 2025 Portfolio in Review

As of Q1 2025, Pfizer held 23 positions worth $501M, down 81% from $2.59B the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Pfizer withdrew a net $1.9B in Q1 2025, closing 2 positions. Its most notable exit was Haleon, an estimated $1.88B position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Pfizer added an estimated $318K to NextCure.

  • Pfizer added most to NextCure in Q1 2025, an estimated $318K increase.
  • Pfizer fully exited Haleon in Q1 2025, selling an estimated $1.88B.
  • Pfizer's ten largest holdings make up 97% of its $501M portfolio in Q1 2025.
  • Pfizer opened 0 new positions and closed 2 in Q1 2025.
  • Pfizer's portfolio value fell 81% quarter-over-quarter to $501M.

Based on Pfizer's 13F filing for Q1 2025, filed 13 May 2025.